Last reviewed · How we verify

Alba Maria Ropero — Portfolio Competitive Intelligence Brief

Alba Maria Ropero pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Co-administration of MMR/YF Co-administration of MMR/YF marketed vaccine Immunology
YF followed by MMR YF followed by MMR marketed
MMR followed by YF MMR followed by YF marketed Live attenuated viral vaccine combination Immunology / Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Aduro Biotech, Inc. · 1 shared drug class
  2. Aeras · 1 shared drug class
  3. Aga Khan University · 1 shared drug class
  4. Aimei Vacin BioPharm (Zhejiang) Co., Ltd. · 1 shared drug class
  5. Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 shared drug class
  6. Asoc. Prof. Erdoğan Selçuk Şeber · 1 shared drug class
  7. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  8. ANRS, Emerging Infectious Diseases · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Alba Maria Ropero:

Cite this brief

Drug Landscape (2026). Alba Maria Ropero — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/alba-maria-ropero. Accessed 2026-05-17.

Related